Ruxience and Sinus disorder - a phase IV clinical study of FDA data

Summary:

Sinus disorder is reported as a side effect among people who take Ruxience (rituximab-pvvr), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Prednisone, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Sinus disorder when taking Ruxience. It is created by eHealthMe based on reports of 4,258 people who have side effects when taking Ruxience from the FDA, and is updated regularly.

What is Ruxience?

Ruxience has active ingredients of rituximab-pvvr. eHealthMe is studying from 4,260 Ruxience users. Check the latest studies of Ruxience.

What is Sinus disorder?

Sinus disorder (disease of sinus) is found to be associated with 1,250 drugs and 1,076 conditions by eHealthMe. Check the latest studies of Sinus disorder.

On Jul, 16, 2026

4,258 people reported to have side effects when taking Ruxience.
Among them, 27 people (0.63%) have Sinus disorder.

Among these 27 people:

How long have people been on Ruxience when they have Sinus disorder? *

What is the gender of people who have Sinus disorder when taking Ruxience? *

female: 85.19 %
male: 14.81 %

What is the age of people who have Sinus disorder when taking Ruxience? *

What are other drugs people take besides Ruxience? *

What are other side effects people have besides Sinus disorder? *

Cough: 10 people, 37.04%
Malaise (a feeling of general discomfort or uneasiness): 8 people, 29.63%
Joint Pain: 8 people, 29.63%
Fever: 8 people, 29.63%
Headache (pain in head): 7 people, 25.93%
Lung Disorder (lung disease): 7 people, 25.93%
Sinusitis (inflammation of sinus): 6 people, 22.22%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 5 people, 18.52%
Rashes (redness): 5 people, 18.52%
Nausea And Vomiting: 5 people, 18.52%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 6 people, 22.22%
Skin Infection: 2 people, 7.41%
Microscopic Polyangiitis (inflammation involving multiple blood or lymph small-vessel): 2 people, 7.41%
Immunodeficiency Common Variable: 2 people, 7.41%
Adenomatous Polyposis Coli ((fap) is an inherited condition in which numerous polyps form mainly in the epithelium of the large intestine): 2 people, 7.41%
Swelling Face: 1 person, 3.70%
Psoriasis (immune-mediated disease that affects the skin): 1 person, 3.70%
Nausea And Vomiting: 1 person, 3.70%
Mouth Ulcers: 1 person, 3.70%
Lupus Vasculitis (a chronic inflammatory autoimmune disorder that may affect blood vessels): 1 person, 3.70%

* Approximation only. Some reports may have incomplete information.

Do you take Ruxience and have Sinus disorder?

- Check whether Sinus disorder is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ruxience:

Ruxience (4,260 reports)

Sinus disorder treatments and more:

Sinus disorder (30,270 reports)

Browse all side effects of Ruxience:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Sinus disorder:

Sinus disorder (1,251 drugs)

Browse all the conditions that are associated with Sinus disorder:

Sinus disorder (1,076 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on rituximab-pvvr (the active ingredients of Ruxience) and Ruxience (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.